PEPGPepGen Inc.

Nasdaq pepgen.com


$ 9.67 $ -0.04 (-0.41 %)    

Friday, 23-Aug-2024 15:59:55 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 9.67
$ 9.67 x 200
-- x --
-- - --
$ 3.72 - $ 19.30
47,681
na
315.14M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-06-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 06-16-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pepgen-q2-eps-087-misses-072-estimate

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.72) by 2...

 hc-wainwright--co-reiterates-buy-on-pepgen-maintains-26-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.

 wedbush-reiterates-outperform-on-pepgen-maintains-20-price-target

Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.

 pepgen-shares-data-from-low-dose-cohort-of-pgn-edo51-in-ongoing-connect1-edo51-phase-2-clinical-trial-for-treatment-of-duchenne-muscular-dystrophy-says-was-well-tolerated-and-all-patients-continued-to-long-term-extension-portion-of-trial-dosing-of-second-cohort-at-10-mgkg-is-ongoing

– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second...

 hc-wainwright--co-reiterates-buy-on-pepgen-maintains-26-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.

 wedbush-reiterates-outperform-on-pepgen-maintains-20-price-target

Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.

 correction-pepgen-q1-2024-gaap-eps-063-beats-074-estimate

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 14....

 insiders-buying-gamestop-and-2-other-stocks

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

 pepgen-reported-march-6-q4-2023-gaap-eps-0810-beats-1010-estimate

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.810) per share which beat the analyst consensus estimate of $(1.010) by 1...

 wedbush-maintains-outperform-on-pepgen-lowers-price-target-to-20

Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $21 to $20.

 pepgen-announces-clearance-of-cta-by-uk-medicines--healthcare-products-regulatory-agency-to-begin-connect2-edo51-a-phase-2-clinical-trial-designed-to-support-potential-accelerated-approval-of-pgn-edo51-for-the-treatment-of-duchenne-muscular-dystrophy

PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies wi...

 over-37m-bet-on-this-industrial-stock-check-out-these-4-stocks-insiders-are-buying

Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION